SCHEMBL3582215

SCHEMBL3582215

COc1ccc(Nc2ncc3cnn(-c4cccc5ccccc45)c3n2)cc1O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 2/20 0.46
CCND1 P24385 2/20 0.46
CCND2 P30279 2/20 0.46
CCND3 P30281 2/20 0.46
AURKB Q96GD4 3/20 0.45
CDC7 O00311 1/20 0.45
AURKA O14965 1/20 0.45
PTK2 Q05397 9/20 0.44
KDR P35968 2/20 0.44
PLK1 P53350 2/20 0.44
INSR P06213 1/20 0.43
WEE1 P30291 1/20 0.42
SYK P43405 1/20 0.42
EGFR P00533 1/20 0.40
FGFR1 P11362 1/20 0.40
EIF2AK4 Q9P2K8 1/20 0.39
JAK2 O60674 1/20 0.39
JAK1 P23458 1/20 0.39
TYK2 P29597 1/20 0.39
JAK3 P52333 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3577978 0.93 CDK4 (0.45) CDK4CCND1CCND2CCND3AURKB
SCHEMBL3581836 0.91 CDK4 (0.49) CDK4CCND1CCND2CCND3AURKA
SCHEMBL3582001 0.86 PTK2 (0.43) CDK4CCND1CCND2CCND3AURKA
SCHEMBL1355866 0.86 CDK4 (0.47) CDK4CCND1CCND2CCND3AURKB
SCHEMBL1355878 0.82 EIF2AK4 (0.49) CDK4CCND1CCND2CCND3AURKB
SCHEMBL1355227 0.82 CDK4 (0.47) CDK4CCND1CCND2CCND3AURKB
SCHEMBL1355944 0.81 EIF2AK4 (0.52) CDK4CCND1CCND2CCND3AURKB
SCHEMBL1355282 0.81 KDR (0.46) CDK4CCND1CCND2CCND3AURKB
SCHEMBL1355858 0.80 EIF2AK4 (0.61) CDK4CCND1CCND2CCND3AURKB
SCHEMBL1355130 0.79 EIF2AK4 (0.50) CDK4CCND1CCND2CCND3AURKB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100190787-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC 2010-07-29 US claimed
EP-2108019-A2 1-H-PYRAZOLO[3,4B]PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES Biogen Idec MA, Inc. (US) 2009-10-14 EP claimed
WO-2008094575-A2 1-H-PYRAZOLO(3,4B)PYRIMIDINE DERIVATIVES AND THEIR USE AS MODULATORS OF MITOTIC KINASES BIOGEN IDEC MA INC. (US) 2008-08-07 WO claimed
US-20100190787-A1 Modulators of Mitotic Kinases BIOGEN IDEC MA INC 2010-07-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100190787-A1 Modulators of Mitotic Kinases CDK1, BUB1, BUB1B CDK4 102/4885CCND1 210/4885CCND2 329/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.